Business Context and Reporting Period
Company: Smith & Nephew plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter 2026 (ended March 28, 2026)
Context: The filing contains a trading update for Q1 2026, highlighting performance in line with expectations, the execution of the "RISE" strategy, and a new share buyback announcement.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Reported Revenue | $1,501 million | $1,407 million | +6.6% |
| Underlying Revenue Growth | 3.1% (excluding FX and acquisitions) | ||
| Adjusted Daily Sales (ADS) Growth | 4.7% (adjusted for one fewer trading day) | ||
| Foreign Exchange Impact | +350 bps tailwind (Euro strengthening vs. USD) | ||
| Free Cash Flow (Full Year Guidance) | ~$800 million | ||
| Trading Profit (Full Year Guidance) | ~$1.3 billion (including Integrity Orthopaedics) | ||
| Share Buyback | $500 million announced |
Material Changes vs. Prior Period
- Revenue Growth: Reported revenue increased 6.6% year-over-year, driven by a 3.1% underlying growth and a 3.5% currency tailwind. Growth was consistent across all business units and regions.
- Business Unit Performance:
- Sports Medicine & ENT: Reported revenue of $491 million (+10.4%). Strong growth in Joint Repair (led by shoulder portfolio) and Arthroscopic Enabling Technologies offset a decline in ENT due to channel inventory reduction in China.
- Advanced Wound Management: Reported revenue of $411 million (+6.6%). Growth in Advanced Wound Care and Devices was offset by a decline in Bioactives due to a reimbursement reset for skin substitutes in the US.
- Orthopaedics: Reported revenue of $599 million (+3.7%). Growth in Hip Implants and non-US Knee Implants offset a 10.3% decline in US Knee Implants as the company manages inventory ahead of new product launches.
- Geographic Performance: Emerging Markets grew 16.0% (reported), led by China. Other Established Markets grew 9.8% (reported), driven by currency effects. The US grew 2.1%.
- Leadership Change: Nathan Folkert appointed as President of Orthopaedics, replacing Craig Gaffin.
Guidance, Outlook, and Risks
Full Year 2026 Guidance (Unchanged)
- Underlying Revenue Growth: Around 6% (reported growth expected at ~7.7%).
- Trading Profit Growth: Around 8% on an organic basis; total trading profit expected at ~$1.3 billion.
- Free Cash Flow: Around $800 million.
- Adjusted ROIC: Greater than 10% (excluding Integrity Orthopaedics impact).
Management Commentary
Management expects revenue and profit growth to be weighted toward the second half of 2026, driven by product launch ramp-ups, stabilization in the US skin substitutes market, and an improving trajectory in US Knee Implants. The company announced a $500 million share buyback to be completed within 12 months, financed by free cash flow and existing balances.
Risks and Contingencies
- Reimbursement Reset: Ongoing impact on skin substitutes in the US, expected to cost $20–$40 million in 2026.
- Tariffs: Expected impact of approximately $60 million in 2026.
- Acquisition Integration: The Integrity Orthopaedics acquisition is expected to be marginally dilutive to trading profit in 2026.
- US Knee Implants: Continued softness anticipated as the company transitions to new kinematic systems (LANDMARK) and manages customer base quality.
Investor Verification Checklist
- Verify the timeline and execution of the new $500 million share buyback program.
- Monitor the stabilization of US skin substitute sales following the reimbursement reset.
- Track the launch and market adoption of the cementless LANDMARK Knee System in Q3 2026.
- Assess the integration progress and financial impact of the Integrity Orthopaedics acquisition.
- Confirm the impact of Volume-Based Procurement (VBP) implementation in China during the second half of 2026.